Skip to main content
SpringerLink
Log in

The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Tamoxifen, a nonsteroidal antiestrogen, is now the endocrine treatment most widely used in breast cancer, both in the adjuvant and advanced disease settings. Here we will trace the development of tamoxifen for advanced breast cancer in postmenopausal patients, consider the biological basis for the recent successful use of tamoxifen for long-term adjuvant therapy, and discuss the use of tamoxifen in premenopausal patients with advanced disease. In part, this will be a historical review offered as a tribute to the late Dr. Arthur L. Walpole, who must receive the chief credit for the discovery of tamoxifen and its subsequent application as an anticancer agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127–205, 1984

    PubMed  Google Scholar 

  2. Baum M and other members of the Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen adjuvant agent in management of early breast cancer. Lancet 1: 257–261, 1983

    PubMed  Google Scholar 

  3. Baum M and other members of the Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet 1: 836–840, 1985

    PubMed  Google Scholar 

  4. Fisher B, Brown A, Wolmark N, Redmond C, Wickerham L, Wittliff J, Dimitrov N, Legault-Poisson S, Schipper H, Prager D and other NSASP investigators prolonging tamoxifen therapy for primary breast cancer: Ann Int Med 106: 649–654, 1987

    PubMed  Google Scholar 

  5. National Institutes of Health consensus development panel on adjuvant chemotherapy and endocrine therapy for breast cancer: Introduction and conclusions, NCI Monographs 1: 1–14, 1986

    Google Scholar 

  6. Harper MJK, Walpole AL: Contrasting endocrine activities ofcis andtrans isomers in a series of substituted triphenylethylenes. Nature (London) 212: 87, 1966

    Google Scholar 

  7. Harper MJK, Walpole AL: A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 13: 101–119, 1967

    PubMed  Google Scholar 

  8. Harper MJK, Walpole AL: Mode of action of ICI46,474 in preventing implantation in rats. J Endocrinol 37: 83–92, 1967

    PubMed  Google Scholar 

  9. Emmens CW: Postcoital contraception. Brit Med Bull 26: 45–51, 1970

    PubMed  Google Scholar 

  10. Klopper A, Hall M: New synthetic agent for the induction of ovulation: preliminary trial in women. Brit Med J 1: 152–154, 1971

    PubMed  Google Scholar 

  11. Williamson JG, Ellis JD: The induction of ovulation by tamoxifen. J Obstet Gynecol Brit Comm 80: 844–847, 1973

    Google Scholar 

  12. Beatson AT: On the treatment of inoperable cases of carcinoma mamma: suggestions for a new method of treatment with illustrative cases. Lancet ii: 104–107, 1896

    Google Scholar 

  13. Kistner RW, Smith OW: Observations on the use of a nonsteroidal estrogen antagonist: MER25. Surg Forum 10: 725–729, 1959

    Google Scholar 

  14. Herbst AL, Griffiths CT, Kistner RW: Clomiphene citrate (NSC-35770) in disseminated mammary carcinoma. Cancer Chem Rep 43: 39–41, 1964

    Google Scholar 

  15. Sander S: Thein vitro uptake of oestradiol in biopsies from 25 breast cancer patients. Acta Path Micobiol Scand (A) 74: 301–302, 1968

    Google Scholar 

  16. Johansson H, Terenius L, Thoren L: The binding of estradiol-17β to human breast cancers and other tissuesin vitro. Cancer Res 30: 692–698, 1970

    PubMed  Google Scholar 

  17. Korenman SG, Dukes BA: Specific estrogen binding by the cytoplasm of human breast carcinoma. J Clin Endocr 30: 639–645, 1970

    PubMed  Google Scholar 

  18. Feherty P, Farrer-Brown G, Kellie AE: Oestradiol receptors in carcinoma and benign disease of the breast: anin vitro assay. Br J Cancer 25: 697–710, 1971

    PubMed  Google Scholar 

  19. Rose FL, Hendry JA, Walpole AL: New cytotoxic agents with tumor-inhibitory activity. Nature (London) 165: 993–996, 1950

    Google Scholar 

  20. Walpole AL: The Walker carcinoma 256 in the screening of tumor inhibitors. Brit J Pharmacol 6: 135–143, 1951

    Google Scholar 

  21. Hendry JA, Rose FL, Walpole AL: Cytotoxic agents: I. Methoyllamide with tumor inhibitory activity and related inactive compounds. Brit J Pharmacol 6: 201–234, 1951

    Google Scholar 

  22. Hendry JA, Homer RF, Rose FL, Walpole AL: Cytotoxic agents: II. bis-epoxides and related compounds. Brit J Pharmacol 6: 235–255, 1951

    Google Scholar 

  23. Hendry JA, Homer RF, Rose FL, Walpole AL: Cytotoxic agents: III. Derivatives of ethyleneimine. Brit J Pharmacol 6: 357–410, 1951

    Google Scholar 

  24. Walpole AL, Roberts DC, Rose FL, Hendry JA, Homer RF: Cytotoxic agents: IV. The carcinogenic actions of some monofunctional ethyleneimine derivatives. Brit J Pharmacol 9: 306–323, 1954

    Google Scholar 

  25. Walpole AL, Williams MHC, Roberts DC: Bladder tumours induced in rats of two strains with 3: 2′dimethyl-4-aminodiphenyl. Br J Cancer 9: 170–179, 1955

    PubMed  Google Scholar 

  26. Walpole AL, Williams MHC: Aromatic amines as carcinogens in industry. Brit Med Bull 14: 141–145, 1958

    PubMed  Google Scholar 

  27. Philips FS, Thiersch JB: The nitrogen mustard-like actions of 2,4,6-tris(ethylenimino)-S-triazine and other bis (ethylenimines). J Pharmacol Expt Therap 100: 398–407, 1950

    Google Scholar 

  28. Buckley SM, Stock CC, Crossley ML, Rhoads CP: Inhibition of the Crocker mouse sarcoma 180 by certain ethylenimine derivatives and related compounds. Cancer 5: 144–152, 1952

    PubMed  Google Scholar 

  29. Karnofsky DA, Burchenal JH, Amistead GC, Southam CM, Bernstein JL, Craver LF, Rhoads CP: Triethylene melamine in the treatment of neoplastic disease. Arch Int Med 87: 477–515, 1951

    Google Scholar 

  30. Paterson E, Boland J: Trisethyleneimino-S-triazine in human malignant disease: a preliminary trial. Brit J Cancer 5: 28–37, 1951

    PubMed  Google Scholar 

  31. Bryan GT, Worzalla JF, Gorske AL, Ramirez G: Plasma levels and urinary excretion of hexamethylmelamine following oral administration to human subjects with cancer. Clin Pharmacol Therap 9: 777–782, 1968

    Google Scholar 

  32. Worzalla JF, Johnson BM, Ramirez G, Bryan GT: N-desmethylation of the antineoplastic agent hexamethylmelamine by rats and man. Cancer Res 33: 2810–2815, 1973

    PubMed  Google Scholar 

  33. Johnson BL, Fisher RI, Bender RA, DeVita VT, Chabner BA, Young RC: Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. Cancer 42: 2157–2161, 1978

    PubMed  Google Scholar 

  34. Foster BJ, Clagett-Carr K, Marsoni S, Simon R, Leyland-Jones B: Role of hexamethylmelamine in the treatment of ovarian cancers: where is the needle in the haystack. Cancer Treat Rep 70: 1003–1014, 1986

    PubMed  Google Scholar 

  35. Bruckner HW: Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack. Cancer Treat Rep 71: 666–668, 1987

    PubMed  Google Scholar 

  36. Walpole AL, Paterson E: Synthetic oestrogens in mammary cancer. Lancet 2: 783–789, 1949

    PubMed  Google Scholar 

  37. Haddow A, Watkinson JM, Paterson E: Influence of synthetic oestrogens upon advanced malignant disease. Brit Med J 2: 393–398, 1944

    Google Scholar 

  38. McGuire WL, Carbone PP, Vollmer EP (eds): Estrogen receptors in human breast cancer. Raven Press, New York, 1975

    Google Scholar 

  39. Jordan VC (ed): Estrogen/Antiestrogen Action and Breast Cancer Therapy. University of Wisconsin Press, Madison, Wisconsin, 1986

    Google Scholar 

  40. Lerner LJ, Holthaus JF, Thompson CR: A nonsteroidal estrogen antagonist (1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl-ethanol. Endocrinology 63: 295–318, 1958

    PubMed  Google Scholar 

  41. Lerner LJ: The first nonsteroidal antioestrogen, MER25. In: Nonsteroidal Antioestrogens. RL Sutherland and VC Jordan (eds), pp. 1–6, Academic Press, Sydney, 1981

    Google Scholar 

  42. Clark JH, Markaverich BM: The agonistic—antagonistic properties of clomiphene: a review. Pharmac Ther 15: 467–519, 1982

    Google Scholar 

  43. Lieberman ME, Gorski J, Jordan VC: An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogensin vitro. J Biol Chem 258: 4741–4745, 1983

    PubMed  Google Scholar 

  44. Skidmore JR, Walpole AL, Woodburn J: Effect of some triphenylethylenes on oestradiol bindingin vitro to macromolecules from uterus and anterior pituitary. J Endocrinol 52: 289–298, 1972

    PubMed  Google Scholar 

  45. Jordan VC, Robinson SP: Species—specific pharmacology of tamoxifen: role of metabolism. Fed Proc 46: 1870–1874, 1987

    PubMed  Google Scholar 

  46. Cole MP, Jones CTA, Todd IDH: A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI46,474. Br J Cancer 25: 270–275, 1971

    PubMed  Google Scholar 

  47. Ward HWC: Antioestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1: 13–14, 1973

    PubMed  Google Scholar 

  48. Anonymous: Breast cancer antioestrogen therapy. Nature 242: 88, 1973

  49. O'Halloran MJ, Maddock PG: ICI46,474 in breast cancer. J Irish Med Assoc 67: 38–39, 1974

    Google Scholar 

  50. Investigational Drug Brochure for ICI46,474, Clinical Research Department, ICI Americas, Inc., March 1974

  51. Jordan VC: Antitumour activity of the antioestrogen ICI46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 5: 354, 1974

    Google Scholar 

  52. Jordan VC: The antiestrogen tamoxifen (ICI46,474) as an antitumor agent. Proceedings of the Eastern Cooperative Oncology Group, Miami, Florida, February 11–12, 1974

  53. Jordan VC: Tamoxifen: mechanism of antitumor activity in animals and man. Proceedings of the Eastern Cooperative Oncology Group, Jaspar, Alberta, June 22–25, 1974

  54. Jordan VC: Effect of tamoxifen (ICI46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12: 419–424, 1976

    PubMed  Google Scholar 

  55. Jordan VC, Koerner S: Tamoxifen as an antitumor agent role of oestradiol and prolactin. J Endocr 68: 305–310, 1976

    PubMed  Google Scholar 

  56. Jordan VC, Koerner S: Tamoxifen (ICI46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 11: 205–206, 1975

    PubMed  Google Scholar 

  57. Nicholson RI, Golder MP: The effect of synthetic antioestrogens on the growth and biochemistry of rat mammary tumours. Eur J Cancer 11: 571–579, 1975

    PubMed  Google Scholar 

  58. Jordan VC: The antitumour effect of tamoxifen in the dimethylbenzanthracene-induced mammary carcinoma model. Proc Symposium on the Hormonal Control of Breast Cancer, Alderley Park, pp 11–17, ICI Pharmaceuticals Division PLC, Macclesfield, 1975

    Google Scholar 

  59. Jordan VC, Dowse LJ: Tamoxifen as an antitumour agent: effect on oestrogen binding. J Endocr 68: 297–303, 1976

    PubMed  Google Scholar 

  60. Jordan VC, Jaspan T: Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumour response. J Endocr 68: 453–460, 1976

    PubMed  Google Scholar 

  61. Nicholson RI, Golder MP, Davis P, Griffiths K: Effects of oestradiol 17β receptors in DMBA-induced rat mammary tumours. Europ J Cancer 12: 711–716, 1976

    Google Scholar 

  62. Proceedings of the Annual Spring Meeting of the Primary Breast Cancer Therapy Group: Tamoxifen workshop (Key Biscayne, Florida, April 28, 1976). Cancer Treat Rep 60: 1409–1466, 1976

    Google Scholar 

  63. Fromson JM, Pearson S, Bramah S: The metabolism of tamoxifen (ICI46,474). Part I. In laboratory animals. Xenobiotica 3: 693–709, 1973

    PubMed  Google Scholar 

  64. Fromson JM, Pearson S, Bramah S: The metabolism of tamoxifen (ICI46,474). Part II. In female patients. Xenobiotica 3: 710–713, 1973

    Google Scholar 

  65. Jordan VC, Collins MM, Rowsby L, Prestwich G: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocr 75: 305–316, 1977

    PubMed  Google Scholar 

  66. Allen KE, Clark ER, Jordan VC: Evidence for the metabolic activation of nonsteroidal antioestrogen: a study of structure-activity relationships. Br J Pharmac 71: 83–91, 1980

    Google Scholar 

  67. Borgna JL, Rochefort H: Hydroxylated metabolites of tamoxifen are formedin vivo and bound to estrogen receptor in target tissues. J Biol Chem 256: 859–868, 1981

    PubMed  Google Scholar 

  68. Adam HK, Douglas EJ, Kemp JV: The metabolism of tamoxifen in humans. Biochem Pharmac 27: 145–147, 1979

    Google Scholar 

  69. Mendenhall DW, Kobayashi H, Shih FML, Sternson LA, Higuchi T, Fabian C: Clinical analysis of tamoxifen on antineoplastic agent in plasma. Clin Chem 24: 1518–1524, 1978

    PubMed  Google Scholar 

  70. Daniel CP, Gaskell SJ, Bishop H, Nicholson RI: Determination of tamoxifen and an hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography-mass spectrometry. J Endocr 83: 401–408, 1979

    PubMed  Google Scholar 

  71. Golander Y, Sternson LA: Paired-ion chromatographic analysis of tamoxifen and two major metabolites in plasma. J Chromatog 181: 41–49, 1980

    Google Scholar 

  72. Adam HK, Gay MA, Moore RH: Measurement of tamoxifen in serum by thin layer densitometry. J Endocr 84: 35–41, 1980

    PubMed  Google Scholar 

  73. Brown RR, Bain RR, Jordan VC: Determination of tamoxifen and metabolites in human serum by high performance liquid chromatography with post-column-fluorescence activation. J Chromat 272: 351–358, 1983

    Google Scholar 

  74. Camaggi CM, Strocchi E, Canova N, Panutti F: High performance liquid chromatographic analysis of tamoxifen and major metabolites in human plasma. J Chromat 275: 436–442, 1983

    Google Scholar 

  75. Milano G, Etienne MC, Frenay M, Khater R, Formento JL, Rennee N, Moll JL, Francoval M, Berto M, Namer M: Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumors. Br J Cancer 55: 509–512, 1987

    PubMed  Google Scholar 

  76. Jordan VC, Bain RR, Brown RR, Gosden B, Santos MA: Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res 43: 1446–1450, 1983

    PubMed  Google Scholar 

  77. Kemp JV, Adam HK, Wakeling AE, Slater R: Identification and biological activity of tamoxifen metabolites in human serum. Biochem Pharmacol 32: 2045–2052, 1983

    PubMed  Google Scholar 

  78. Lippman ME, Bolan G: Oestrogen—responsive human breast cancer in long-term tissue culture. Nature 256: 592–595, 1975

    PubMed  Google Scholar 

  79. Brooks SC, Locke ER, Soule HD: Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248: 6251–6253, 1973

    PubMed  Google Scholar 

  80. Osborne CK, Boldt DH, Clark GM, Trent JM. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 43: 3583–3585, 1983

    PubMed  Google Scholar 

  81. Sutherland RL, Green MD, Hall RE, Reddel RR, Taylor IW: Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 19: 615–621, 1983

    PubMed  Google Scholar 

  82. Fisher B, Carbone PP, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Kataryck DL, Wolmark N, Fisher ER: L—phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 292: 117–122, 1975

    PubMed  Google Scholar 

  83. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brombilla C, DeLena M, Tancini G, Bajetta E, Musumerci R, Veronesi U: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410, 1976

    PubMed  Google Scholar 

  84. Jordan VC: Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen treatment as a potential adjuvant therapy. Rev Endocr Rel Cancer (October Suppl): 49–55, 1978

    Google Scholar 

  85. Jordan VC, Dix CJ, Allen KE: The effectiveness of longterm treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Adjuvant Therapy of Cancer II, Salmone SE, Jones SE (eds) Grune and Stratton, New York, 1979, pp 19–26

    Google Scholar 

  86. Jordan VC, Allen KE, Dix CJ: The pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64: 745–759, 1980

    PubMed  Google Scholar 

  87. Jordan VC, Allen KE: Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16: 239–251, 1980

    PubMed  Google Scholar 

  88. Robinson SP, Jordan VC: The reversal of the antitumor effect of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene induced rat mammary carcinoma model. Cancer Res 47: 5386–5390, 1987

    PubMed  Google Scholar 

  89. Wilson AJ, Tehrani F, Baum M: Adjuvant tamoxifen therapy for early breast cancer: an experimental study with reference to oestrogen and progesterone receptors. Br J Surg 69: 121–125, 1982

    PubMed  Google Scholar 

  90. Gottardis MM, Jordan VC: The antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47: 4020–4024, 1987

    PubMed  Google Scholar 

  91. Osborne CK, Hobbs K, Clark GM: Effects of estrogens and antiestrogens on growth of human breast cancer cells in athymic mice. Cancer Res 45: 584–590, 1985

    PubMed  Google Scholar 

  92. Osborne CK, Conarado EB, Robinson JP: Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23: 1189–1196, 1987

    PubMed  Google Scholar 

  93. Gottardis MM, Robinson SP, Jordan VC: Estradiol—stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 29: 57–60, 1988

    PubMed  Google Scholar 

  94. Ludwig Breast Cancer Group randomized trial of chemoendocrine therapy, endocrine therapy and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases. Lancet 1: 1256–1260, 1984

    Google Scholar 

  95. Pritchard KI, Meakin JW, Boyd NF, Ambus K, DeBoer G, Dembo AJ, Paterson AHG, Sutherland DJA, Wilkinson RH, Bassett AA, Evans WK, Beale FA, Clark RM, Keane TJ: A randomized trial of adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer. In: Adjuvant Therapy of Breast Cancer IV, Jones SE, Salmon SE (eds), Grune and Stratton, New York, 1984, pp 339–348

    Google Scholar 

  96. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blicher-Toft M, Rasmussens BB: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1: 16–29, 1985

    PubMed  Google Scholar 

  97. Wallgren A, Baral E, Castensen J, Friberg S, Glas U, Hjalmar JL, Kargas M, Nordenskjold B, Skoog L, There N-O, Wilking N: Should adjuvant tamoxifen be given for several years in breast cancer? In: Adjuvant Therapy of Breast Cancer IV, Jones SE, Salmon SE (eds), Grune and Stratton, New York, 1984, pp 331–338

    Google Scholar 

  98. Ribeiro G, Palmer MK: Adjuvant tamoxifen for operable carcinoma of the breast: report of a clinical trial by the Christie Hospital and Holt Radium Institute. Br Med J 286: 827–830, 1983

    Google Scholar 

  99. Ribeiro G, Swindell R: The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinomaseven-year results. Eur J Cancer Clin Oncol 21: 897–900, 1985

    PubMed  Google Scholar 

  100. Cummings FJ, Gray R, Davis TE, Tormey DC, Harris JE, Falkson G, Arsenau J: Adjuvant tamoxifen treatment of elderley women with stage II breast cancer. Annal Int Med 103: 324–329, 1985

    Google Scholar 

  101. Delozier T, Julien J-P, Juret P, Veyret C, Couette J-E, Grai Y, Olliver J-M, de Ranieri E: Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial. Breast Cancer Res Treat 7: 105–110, 1986

    PubMed  Google Scholar 

  102. Breast Cancer Trials Committee, Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet ii: 171–175, 1987

    Google Scholar 

  103. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff JL, Fisher ER, Plotkin D, Sachs S, Wolter J, Frelick R, Desser R, Licalzi N, Geggie P, Campbell T, Elias EG, Prager D, Koontz P, Volk H, Dimitrov N, Gardner B, Lerner H, Shibata H and other NSABP investigators: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305: 1–6, 1981

    PubMed  Google Scholar 

  104. Fisher B, Redmond C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S, Saffer EA and other NSABP investigators: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 4: 459–471, 1986

    PubMed  Google Scholar 

  105. Fisher B, Redmond C, Fisher ER, Wolmark N: Systemic adjuvant therapy in the treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Experience. NCI Monograph 1: 35–43, 1986

    Google Scholar 

  106. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Escher G, Lippman ME, Savlov E, Wittliff JL, Fisher ER and other NSABP investigators: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1: 227–241, 1983

    PubMed  Google Scholar 

  107. Tormey DC, Jordan VC: Long-term tamoxifen adjuvant therapy in node positive breast cancer — a metabolic and pilot clinical study. Breast Cancer Res Treat 4: 297–302, 1984

    PubMed  Google Scholar 

  108. Tormey DC, Rasmussen P, Jordan VC: Update on longterm tamoxifen study (Letter to the Editor). Breast Cancer Res Treat 9: 157–158, 1987

    PubMed  Google Scholar 

  109. Jordan VC, Fritz NF, Tormey DC: Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 47: 624–630, 1987

    PubMed  Google Scholar 

  110. Jordan VC, Fritz NF, Tormey DC: Long-term adjuvant therapy with tamoxifen effects on sex hormone binding globulin and antithrombin III. Cancer Res 47: 4517–4519, 1987

    PubMed  Google Scholar 

  111. El-Sheikha Z, Klopper A, Beck JS: Treatment of menometrorrhagia with an antioestrogen. Clin Endocrinol 1: 275–282, 1972

    Google Scholar 

  112. Groom GV, Griffiths K: Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, folliclestimulating hormone, prolactin, oestradiol and progesterone in normal premenopausal women. J Endocrinol 70: 421–428, 1976

    PubMed  Google Scholar 

  113. Senior BE, Cawood ML, Oakey RE, McKiddie JM, Siddle DR: A comparison of the effects of clomiphene and tamoxifen treatment on the concentrations of oestradiol and progesterone in the peripheral plasma of infertile women. Clin Endocrinol 8: 381–389, 1978

    Google Scholar 

  114. Manni A, Trujillo JE, Marshall JS, Brodkey J, Pearson OH: Antihormone treatments of stage IV breast cancer. Cancer 43: 444–450, 1979

    PubMed  Google Scholar 

  115. Sherman BM, Chapler FK, Crickard K, Wycoff D: Endocrine consequences of continuous antioestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 64: 398–404, 1979

    PubMed  Google Scholar 

  116. Rose DP, Davis TE: Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res 40: 4043–4047, 1980

    PubMed  Google Scholar 

  117. Tajima C, Fukushima T: Endocrine profiles in tamoxifeninduced ovulatory cycles. Fertil Steril 40: 23–27, 1983

    PubMed  Google Scholar 

  118. Dnistrian AM, Greenberg EJ, Dillon HJ, Hakes TB, Fracchia AA, Schwartz MK: Chemohormonal therapy and endocrine function in breast cancer patients. Cancer 56: 63–70, 1985

    PubMed  Google Scholar 

  119. Ravdin PM, Fritz NF, Tormey DC, Jordan VC: Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48: 1026–1029, 1988

    PubMed  Google Scholar 

  120. Pritchard KI, Thomson DB, Meyers RE, Sutherland DJA, Mobbs BG, Meakin JW: Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787–796, 1980

    PubMed  Google Scholar 

  121. Kalman AM, Thompson T, Vogel CL: Response to oophorectomy after tamoxifen failure in a premenopausal patient. Cancer Treat Rep 66: 1867–1868, 1982

    PubMed  Google Scholar 

  122. Planting AST, Alexiera-Figusch J, Blonk-Wijst J, van Patten WLJ: Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer Treat Rep 69: 363–368, 1985

    PubMed  Google Scholar 

  123. Sawka CA, Pritchard KI, Paterson DJA, Thomson DB, Skelley WE, Myers RE, Mobbs BG, Malkin A, Meakin JW: Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast cancer. Cancer Res 46: 3152–3256, 1986

    PubMed  Google Scholar 

  124. Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahman DL, Chang MN, Bisel HF, Windschitl HE, Twito DI, Pfeifle DM: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 178–185, 1986

    PubMed  Google Scholar 

  125. Buchanan RB, Blamey RW, Durrent KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4: 1326–1330, 1986

    PubMed  Google Scholar 

  126. Turner RT, Wakeley GK, Hannon KS, Bell NH: Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Min Res 2: 449–456, 1987

    Google Scholar 

  127. Jordan VC, Phelps E, Lingren JU: Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10: 31–35, 1987

    PubMed  Google Scholar 

  128. Love RR, Mazess RB, Tormey DC, Rasmussen P, Jordan VC: Bone mineral density in women with breast cancer treated with tamoxifen for two years. Breast Cancer Res Treat 10: 112, Abstract 109, 1987

    Google Scholar 

  129. Kossner S, Wallgren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52: 339–349, 1984

    PubMed  Google Scholar 

  130. Enk RE, Rios CN: Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53: 2607–2609, 1984

    PubMed  Google Scholar 

  131. Jordan VC, Fenuik L, Allen KE, Cotton RC, Richardson DN, Walpole AL, Bowler J: Structural derivatives of tamoxifen and oestradiol 3 methylether as potential alkylating antioestrogens. Eur J Cancer Clin Oncol 17: 193–200, 1981

    Google Scholar 

  132. Robertson DW, Wei LL, Hayes JR, Carlson KE, Katzenellenbogen JA, Katzenellenbogen BS: Tamoxifen aziridines: effective inactivation of the estrogen receptor. Endocrinology 109: 1298–1300, 1981.

    PubMed  Google Scholar 

  133. Katzenellenbogen JA, Carlson KE, Heiman DF, Robertson DW, Wei LL, Katzenellenbogen BS: Efficient and highly selective covalent labeling of the estrogen receptor with [3H]tamoxifen aziridine. J Biol Chem 258: 3487–3495, 1983

    PubMed  Google Scholar 

  134. Bucourt R, Vignau M, Torelli V, Richard-Roytt, Geynet C, Secco-Millet C, Redcailh G, Baulieu EE: New biospecific adsorbents for the purification of estradiol receptor. J Biol Chem 253: 8221–8228, 1978

    PubMed  Google Scholar 

  135. Wakeling AE, Bowler J: Steroidal pure antioestrogens. J Endocrinol 112: R7-R10, 1987

    PubMed  Google Scholar 

  136. Dutta AS, Furr BJA, Giles MB, Valacaccia B, Walpole AL: Potent agonist and antagonist analogues of luliberin containing an azaglycine residue in position 10. Biochem Biophys Res Comm 81: 382–385, 1978

    PubMed  Google Scholar 

  137. Furr BJA, Nicholson RI: Use of analogues of LHRH for the treatment of cancer. J Reprod Fertil 64: 529–539, 1982

    PubMed  Google Scholar 

  138. Ahmed SR, Brooman PJC, Schalet SM, Howell A, Blacklock NJ, Richards P: Treatment of advanced prostatic cancer with LHRH analogue ICI118,630: clinical response and hormonal mechanisms. Lancet 2: 415–419, 1983

    PubMed  Google Scholar 

  139. Ahmann FR, Citrin DL, deHaan HA, Guinan P, Jordan VC, Kreis W, Scott M, Trump DL: Zoladex: a sustained release monthly luteinizing hormone releasing hormone analogue for the treatment of advanced prostate cancer. J Clin Oncol 5: 912–917, 1987

    PubMed  Google Scholar 

  140. Nicholson RI, Walker KJ, Turkes A, Turkes AO, Dyas J, Blamey RW, Cambell FC, Robinson MRG, Griffiths K: Therapeutic significance and the mechanism of action of the LH-RH agonist, ICI118,630, in breast cancer and prostate cancer. J Steroid Biochem 20: 129–135, 1984

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Oncology and Pharmacology, University of Wisconsin Clinical Cancer Center, 600 Highland Avenue, 53792, Madison, WI, USA

    V. Craig Jordan

Authors
  1. V. Craig Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jordan, V.C. The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole. Breast Cancer Res Tr 11, 197–209 (1988). https://doi.org/10.1007/BF01807278

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01807278

Key words

Search

Navigation